Leadership & Pay ·
Vir Biotechnology appointed Aziz Sawaf as Executive Vice President and Chief Financial Officer effective October 5, 2026
VIRVir Biotechnology, Inc.
Vir Biotechnology appointed Aziz Sawaf as Executive Vice President and Chief Financial Officer effective October 5, 2026. Sawaf succeeds Brent Sabatini as principal financial officer while retaining his role as Senior Vice President and Chief Accounting Officer. Sawaf brings over 20 years of experience, previously serving as CFO at Theravance Biopharma since 2023 and holding roles at Gilead Sciences. His compensation includes a $520,000 annual base salary, a target bonus of 45%, a $150,000 one-time sign-on bonus, and equity awards comprising 150,000 stock options and 75,000 restricted stock units. Vir Biotechnology is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for serious infectious diseases and cancer.